Spots Global Cancer Trial Database for xelox
Every month we try and update this database with for xelox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer | NCT03565029 | Colo-rectal Can... | XELOX Radiotherapy | 18 Years - | Niguarda Hospital | |
| Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer | NCT02745639 | Rectal Neoplasm... | VMAT-SIB XELOX | 18 Years - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients | NCT02291744 | Metastatic Colo... | resection of pr... XELOX | 18 Years - 75 Years | Fudan University | |
| Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | NCT04008511 | Metastatic Colo... | Regorafenib Regorafenib Capecitabine Oxaliplatin | 18 Years - 75 Years | China Medical University, China | |
| KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer | NCT03342937 | Gastric Cancer Esophagus Cance... | Oxaliplatin+Cap... | 18 Years - | Duke University | |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | NCT00127036 | Adenocarcinoma Colon Cancer | XELOX XELIRI Bevacizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer | NCT03511170 | Colorectal Neop... Chemotherapy | XELIRI XELOX | 18 Years - 75 Years | Harbin Medical University | |
| RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX | NCT01049620 | Advanced Gastri... | RAD001, Capecit... | 18 Years - 70 Years | Asan Medical Center | |
| Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis | NCT04943653 | Stomach Neoplas... Paclitaxel Peritoneal Meta... | Paclitaxel | 20 Years - 80 Years | Seoul St. Mary's Hospital | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | NCT06346197 | Gastric Cancer MSI-H Metastatic Canc... Advanced Cancer | Balstilimab Botensilimab Folfox Protocol XELOX Nivolumab | 18 Years - | Centre Leon Berard | |
| Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer | NCT02022852 | Rectal Cancer | Capecitabine XELOX | 18 Years - | Harbin Medical University | |
| Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | NCT03666442 | Rectal Cancer | XELOX | 20 Years - 75 Years | West China Hospital | |
| The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | NCT04416854 | Metastatic Colo... Surgery | resection of pr... XELOX mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) | NCT01748851 | Gastric Carcino... | XELOX FOLFOX | 20 Years - | Dong-A University Hospital | |
| PRECISE CURATE.AI Pilot Clinical Trial | NCT04522284 | Solid Tumor | CURATE.AI Capecitabine XELOX XELIRI Ibrutinib | 21 Years - 99 Years | National University Hospital, Singapore | |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer | NCT05420584 | Rectal Neoplasm... | Arterial chemoe... Tislelizumab In... XELOX Pelvic MRI Laparoscopic ra... | 18 Years - 75 Years | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC) | NCT00997685 | Potentially Res... Colorectal Canc... | Capecitabine pl... | 18 Years - 65 Years | Guangdong Provincial People's Hospital | |
| ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | NCT06242418 | Colon Cancer | FOLFOXIRI XELOX | 18 Years - 75 Years | West China Hospital | |
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery | NCT05468138 | MSI-H PD-1 Immunother... Gastric Cancer Adjuvant Therap... | SOX XELOX Observation PD-1 antibody | 18 Years - 75 Years | Fudan University | |
| Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | NCT01490749 | Esophageal Canc... Neoplasms, Esop... | RAD001 XELOX Carboplatin Radiation | 18 Years - | Emory University | |
| Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers | NCT02934464 | Stomach Neoplas... | RAMUCIRUMAB Paclitaxel FOLFOX 4 mFOLFOX 6 XELOX | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis | NCT02380131 | HER-2 Positive ... Liver Metastasi... | Oxaliplatin plu... Herceptin | 18 Years - 75 Years | Hebei Medical University | |
| A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients | NCT02291744 | Metastatic Colo... | resection of pr... XELOX | 18 Years - 75 Years | Fudan University | |
| Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | NCT00127036 | Adenocarcinoma Colon Cancer | XELOX XELIRI Bevacizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy | NCT02250209 | Gastric Cancer | Trastuzumab Capecitabine Oxaliplatin | 18 Years - 80 Years | Chinese PLA General Hospital | |
| XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer | NCT03511170 | Colorectal Neop... Chemotherapy | XELIRI XELOX | 18 Years - 75 Years | Harbin Medical University | |
| XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma | NCT03355612 | Gastric Carcino... | Apatinib XELOX | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | NCT04380337 | Rectal Cancer | FOLFOXIRI FOLFOX regimen XELOX IMRT | 18 Years - | Stanford University | |
| Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer | NCT00443573 | Colon Cancer | recombinant nem... | 18 Years - 75 Years | ARCA Biopharma, Inc. | |
| Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer | NCT05420584 | Rectal Neoplasm... | Arterial chemoe... Tislelizumab In... XELOX Pelvic MRI Laparoscopic ra... | 18 Years - 75 Years | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX | NCT01396707 | Metastatic or R... Her-2 Positive ... | Herceptin+XELOX | 20 Years - | Asan Medical Center | |
| Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation | NCT03671252 | Rectal Cancer | FOLFOXIRI XELOX Chemoradiothera... TME operation efficacy evalua... | 18 Years - 75 Years | Sun Yat-sen University | |
| An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | NCT03662659 | Gastric Cancer Cancer of the S... Esophagogastric... | BMS-986213 Nivolumab XELOX FOLFOX SOX | 18 Years - | Bristol-Myers Squibb | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma | NCT05494060 | Carcinoma Gastrointestina... Stomach Cancer Gastroesophagea... Digestive Syste... Gastric Cancer Gastrointestina... | Anlotinib hydro... Penpulimab Inje... XELOX | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | NCT05985707 | HER2-positive C... HER2-positive B... | KN026 KN046 XELOX | 18 Years - | Peking University Cancer Hospital & Institute | |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | NCT04281576 | Gastric Cancer GastroEsophagea... | NovoTTF-100L(P) Oxaliplatin Capecitabine Trastuzumab | 18 Years - | NovoCure Ltd. | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients | NCT01618474 | Stomach Cancer | DX XELOX | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer | NCT02870153 | Colorectal Neop... | SOX XELOX | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| Effect and Safety of Adjuvant Huaier Granule Versus Standard Chemotherapy Regimens in Gastric Cancer Patients | NCT05498766 | Gastric Cancer | Huaier granule Oxaliplatin Tegafur, Gimera... Capecitabine | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Perioperative FLOT vs Adjuvant XELOX for CA Stomach | NCT05264896 | Cancer of Stoma... | 5-FU, Leucovori... XELOX | 18 Years - | Chinese University of Hong Kong | |
| Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients | NCT02510118 | Colon Cancer | mFOLFOX6 XELOX Placebo ChangTa... ChangTai Keli | 18 Years - 75 Years | Nanjing NingQi Medicine Science and Technology Co., Ltd. | |
| Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma | NCT01880632 | Gastric Adenoca... | XELOX | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Perioperative FLOT vs Adjuvant XELOX for CA Stomach | NCT05264896 | Cancer of Stoma... | 5-FU, Leucovori... XELOX | 18 Years - | Chinese University of Hong Kong | |
| Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma | NCT01552967 | Colorectal Aden... | Capecitabine | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. | NCT00349336 | Colorectal Canc... | bevacizumab [Av... XELOX bevacizumab [Av... FOLFOX-4 | 18 Years - | Hoffmann-La Roche | |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC | NCT06023758 | HER2-positive L... | KN026 KN046 XELOX | 18 Years - 75 Years | Peking University | |
| Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | NCT01490749 | Esophageal Canc... Neoplasms, Esop... | RAD001 XELOX Carboplatin Radiation | 18 Years - | Emory University | |
| A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. | NCT00349336 | Colorectal Canc... | bevacizumab [Av... XELOX bevacizumab [Av... FOLFOX-4 | 18 Years - | Hoffmann-La Roche | |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | NCT04659382 | Metastatic Colo... pMMR MSS Immune Checkpoi... Internal Radiot... | Atezolizumab Therasphere XELOX Bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer | NCT01470742 | Gastric Cancer | XELOX XELODA | 70 Years - | Samsung Medical Center | |
| Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer | NCT03565029 | Colo-rectal Can... | XELOX Radiotherapy | 18 Years - | Niguarda Hospital | |
| A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | NCT04543695 | Rectal Cancer | Concurrent Chem... XELOX mFOLFOX TME | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | NCT04543695 | Rectal Cancer | Concurrent Chem... XELOX mFOLFOX TME | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer | NCT01470742 | Gastric Cancer | XELOX XELODA | 70 Years - | Samsung Medical Center | |
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery | NCT05468138 | MSI-H PD-1 Immunother... Gastric Cancer Adjuvant Therap... | SOX XELOX Observation PD-1 antibody | 18 Years - 75 Years | Fudan University | |
| Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer | NCT03484221 | Rectal Neoplasm... Drug Therapy Radiation | FOLFOXIRI Short-Course Ra... XELOX | 18 Years - 75 Years | China Medical University, China | |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | NCT06196697 | Gastric Adenoca... Gastroesophagea... | Cadonilimab Ivonescimab XELOX SOX | 18 Years - 75 Years | Harbin Medical University | |
| The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | NCT04416854 | Metastatic Colo... Surgery | resection of pr... XELOX mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer | NCT03511170 | Colorectal Neop... Chemotherapy | XELIRI XELOX | 18 Years - 75 Years | Harbin Medical University | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | NCT05228431 | Advanced Rectal... | XELOX Capecitabine mo... Radiation | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
